Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > BASHER FRENZY
View:
Post by capebretongirl on May 19, 2021 11:38am

BASHER FRENZY

Sad to visit this board for a variety of reasons. First of all the sp is depressing to watch after a $1.57 march - only the bashers/shorters are happy with that because they have won the shorter battle. Secondly, reading the scathing nonesense here by the gleeful warts scattering this board is nauseating even for the heartiest stomachs. The only bright light I see right now sp wise is that we have to be near the bottom - I mean how can we go lower than this on a company with $6.5 million in the bank and $2.5 million rolling in each quarter.  Tripp dropped the ball with the rollout and initial shock of CARE, however to his credit he has gone out of the way via CCs, Investor tel interviews, Linkedin, FAQs to counter this and educate us.  That education shows a company that needs a CARE in order to operate in this telehealh environment. The AVRT program is not the leading solution for cancer treatment in the US, however we don't need 100% of that business when in fact about 1% would propel our market cap.  This is a cancer diagnosis/treatment starved environment and we do have a modest solution. Tripp has stated there will be other affiliations announced in the near term so obviously he is working on them as we speak. Ichor and Mercer are still our friends and giants like Rexall are in the wings - there is also a hint of another Fortune 500 company out there. Tripp wants covid to convert to cancer treatment and no one can argue that is vision is not bang on - he is going after the big clients.

Sure, we would all like to see an immediate announcement of affiliation with Johnson and Johnson or Pfiser but thats not going to happen - we have to crawl before we walk. The optimists here believe that one morning we will see an NR announcing a big development with a big player and the sp will react accordingly. I am here simply because I believe that will happen and don't want to be on the outside looking in when it does - that will be a sad say for the shorters' accounts and I look forward to it.
Comment by KVDollars on May 19, 2021 11:43am
Bequiet  with your sob story... At the end Managment needs to deliver that is all.   Forget the shorts.. If the company deliver, it will burn through shorts... Thats the end of the story managment needs to deliver and when they do then it will be golden
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities